ICER says it's fair for Bio­Marin and CSL to price in­com­ing he­mo­phil­ia gene ther­a­pies at $2M-$3M

Get ready for mil­lion-plus-dol­lar gene ther­a­pies to be­come the norm rather than the ex­cep­tion, and in some cas­es, the Boston-based drug pric­ing watch­dog ICER is com­ing on board.

The non­prof­it ICER (In­sti­tute for Clin­i­cal and Eco­nom­ic Re­view) on Wednes­day un­veiled a new re­port find­ing that CSL Behring’s po­ten­tial gene ther­a­py etranaco­gene deza­parvovec for he­mo­phil­ia B, which is due for an FDA ap­proval de­ci­sion by the end of this month, could be fair­ly priced at around $3 mil­lion. ICER al­so up­dat­ed its pre­vi­ous as­sess­ment of Bio­Marin’s EU-au­tho­rized he­mo­phil­ia A gene ther­a­py Roc­ta­vian, which ICER said could be fair­ly priced at about $2 mil­lion.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.


Alexandria Real Estate Equities

Cambridge, MA, USA